The Association for Clinical Oncology established the ASCO Patient-Centered Cancer Care Certification, a new pilot certifying outpatient oncology group practices and health systems that meet a single set of comprehensive, expert-backed standards for patient-centered care delivery.
City of Hope plans to hold its 16th annual Songs of Hope celebration virtually on Sept. 30, 2021, at 5:30 p.m. PDT.
Prebys Cancer Center, a new comprehensive cancer care facility, opened its doors Sept. 13 to patients from central and south San Diego County.
Updated results from CStone Pharmaceuticals’ phase III GEMSTONE-302 study indicate the effectiveness of the antibody sugemalimab in combination with chemotherapy as a first-line treatment for patients with stage IV non-small cell lung cancer.
Cabometyx (cabozantinib) offers efficacy benefits in combination with Bristol Myers Squibb’s Opdivo (nivolumab) versus sunitinib for patients with previously untreated advanced renal cell carcinoma, regardless of prior nephrectomy status, according to data from a post-hoc exploratory analysis of the phase III CheckMate -9ER pivotal trial.
The Leukemia & Lymphoma Society published a study showing that more than one in two patients with B-cell blood cancers produced antibodies to a third dose of COVID-19 vaccine, despite having no detectable antibodies after the first two doses.
Researchers at MD Anderson Cancer Center demonstrated that stereotactic ablative radiotherapy was as effective as surgery at providing long-term benefits to patients with operable early-stage non-small cell lung cancer and generated minimal side effects.
Keck School of Medicine of USC researchers found that children born with a genetic predisposition to produce more lymphocytes, particularly in relation to other types of white blood cells, are at a higher risk of developing acute lymphoblastic leukemia.
Cedars-Sinai Cancer and Tempus, an artificial intelligence and precision medicine company, are using big data and AI to design personalized cancer treatment options, creating virtual replicas of patients’ DNA, RNA, protein and other information to help identify the most effective approach to each individual’s disease.
Exkivity (mobocertinib) was granted FDA accelerated approval for adult patients with locally advanced or metastatic non-small cell lung cancer with epidermal growth factor receptor exon 20 insertion mutations, as detected by an FDA-approved test, whose disease has progressed on or after platinum-based chemotherapy.
